Enlarge this image AbbVie’s Humira was the world’s best-selling drug for many years. Now it faces competition for copycats that cost a…
Topics
biosimilar
-
-
News
AbbVie’s blockbuster drug Humira finally loses its 20-year, $200 billion monopoly
by Dan Gorenstein January 31, 2023Enlarge this image Humira, the injectable biologic treatment for rheumatoid arthritis, now faces its first competition from one of several copycat “biosimilar”…
-
News
Why The U.S. Remains The Most Expensive Market For ‘Biologic’ Drugs In The World
by Sarah Jane Tribble December 19, 2018Enlarge this image Susie Christoff tried several drugs to cope with her painful psoriatic arthritis before finding Cosentyx worked the best. The…
-
Enlarge this image A patient with Crohn’s disease receives an IV infusion of Remicade, or infliximab. Dr P. Marazzi/Science Source hide caption…